Pigmentation Disorders Treatment Market

Pigmentation Disorders Treatment Market Size Survey Report – In a Glance

As per the survey report on global Pigmentation disorders treatment market, the market is projected to foresee a CAGR of CAGR value 9.1% between 2024-2033, and further generate a market size of USD 15.5 billion revenue by the end of 2033. In the year 2024, the market size was valued at USD 7.4 billion revenue.

• The global Pigmentation disorders treatment market is projected to grow on account of the rising prevalence of skin disorders.
• In Japan, the Pigmentation disorders treatment market growth can be attributed to the fuelling older population.
• KDMI analyst’s growth analysis foresees side effects and efficacy concerns to challenge the market growth.
• North America, having the highest market share in the Pigmentation disorders treatment market, is projected to dominate the global market.

Pigmentation Disorders Treatment Market Analysis

Pigmentation disorders can be described as the condition in which the skin color gets affected which can be caused by excess or deficiency of melanin, the pigment responsible for coloration. The pigmentation market has been surging across the globe due to the increasing incidence of skin disorders in recent times. Several factors such as prolonged sun exposure, hormonal changes, particularly during pregnancy or due to hormonal therapies, and environmental pollution can lead to melasma, age spots, inflammation, or post-inflammatory hyperpigmentation. The report states that skin conditions are assumed to affect 1.8 billion people at any point in time in total and skin infections, which can be of bacterial, viral, fungal, or parasitic origin, are the chief cause of disease, especially in tropical and resource-poor settings. The latest meta-study performed in 2020 revealed that the average ratio of pigmentary disorders, was 16.1%, while the most common pigmentary condition was melanocytic nevi at 54.2%, followed by post-inflammatory pigmentation and vitiligo accounting for 47% and 6%, respectively. Another study suggests that around 223 million people are dealing with atopic dermatitis in 2022, of which approximately 43 million are aged 1-4. GLENMARK PHARMACEUTICALS LTD, Novartis AG, Pfizer Inc., are some of the significant parties in the global market for Pigmentation disorders treatment.

Analyst’s Observation on Japan Pigmentation Disorders Treatment Market Survey

In Japan, the market growth for Pigmentation disorders treatment can be attributed to the fuelling older population. Older people are more prone to certain pigmentation conditions as the senescent skin becomes more deficient in blood vessels, causing the older skin to look more visibly paler. Japan is turning greyer day by day and an unprecedented number of people are celebrating their 100th birthday. According to the national data, it has been reported that greater than 1 in 10 individuals in the country have now reached 80 years or older and nearly a third of its population is over 65 – an estimated 36.23 million. Viewing the world in 2050, the people in Japan will continue to grow, although at a gradual pace, with an average life expectancy of 77.2 years (equivalent to that of [≈] Japan in 1983) and an older (aged over 65 years) population of 16.5% (≈Japan in 1983). In contrast, the reduction in the Japanese population will quicken, with life expectancy expected to attain 88.3 years and the older population to climb to 37.5%, which is on the verge of the peak. Obagi Cosmeceuticals LLC, Galderma S.A., Viatris, Inc. (Mylan N.V.), are some of the significant parties in the market for Pigmentation disorders treatment in Japan.

Pigmentation Disorders Treatment Market Growth Driver and Challenges

Growth Driver

Rise of telemedicine:

The rise of telemedicine offers a remarkable opportunity for the pigmentation disorders treatment market as it facilitates patients to access specialized dermatological care virtually or from far away allowing people, especially those in rural or low-access regions, to consult with dermatologists without the need for long-distance travel. Patients can also receive ongoing follow-ups and track their conditions from the comfort of their homes, leading to increased involvement and adherence to treatment plans. Many countries in the European Region have witnessed rapid improvements in the adoption and use of telehealth and other digital health solutions from the dawn of the pandemic. As per the regional survey, teleradiology is driving the direction, with 84% of countries reporting its use. Moreover, telepsychiatry and telemedicine are also on the rise, with 51% of countries offering telepsychiatry and 77% providing telemedicine or remote patient monitoring services. With the increasing adoption of telehealth solutions by healthcare providers, the availability of pigmentation disorder treatment will also rise, driving market growth and improving overall effectiveness in skin health management.

Restraint

Side effects and efficacy concerns:

Side effects and inconsistent results pose a major challenge in the pigmentation disorders treatment market putting an obstacle in its growth. Treatments, such as topical agents and chemical peels, can result in adverse reactions such as skin irritation, redness, or allergic responses, specifically in individuals with sensitive skin. Furthermore, the therapeutic effectiveness can differ extensively based on factors such as skin type, the severity of the condition, and adherence to prescribed regimens which can result in patient dissatisfaction and a lack of trust in specific therapies. A study revealed that the pigmentation caused due to drug administration represents 10 to 20% of all cases of acquired hyperpigmentation, which was more common in elderly people.

Pigmentation Disorders Treatment Market Segmentation

Our experts at KD Market Insights have segmented the global Pigmentation disorders treatment market research report as:

Pigmentation Disorders Treatment Market Regional Synopsis

The North America Pigmentation disorders treatment market is majorly driven by growing prevalence of pigmentation disorders, a well-established healthcare system, a surge in research and development activities, and companies embracing forward-thinking strategies to meet the growing needs of the market. Reports indicate that atopic dermatitis has an effect on almost 1 in 10 Americans of all ages, psoriasis affects close to 7.5 million people in the United States and acne is the most widespread dermatological condition in the United States, affecting up to 50 million Americans yearly. Acne usually typically starts during adolescence and affects many adolescents and young adults. Despite that, it can occur at any point in life and may continue into one’s 30s and 40s. Additionally, adult acne keeps increasing and affects up to 15% of women.

The Asia-Pacific region is forecasted to see considerable expansion during the time period, propelled by the growing geriatric population and increased research and development in the skincare solutions sector. The growing financial contribution to the healthcare sector, along with growing government efforts aimed at strengthening health outcomes, are also catalyzing this growth, making the region a vital player in the pigmentation disorders treatment market. As per survey reports, one in four people in Asia and the Pacific will be older than 60 years old by 2050 and the population of older persons (aged over 60) in the region will triple between 2010 and 2050, reaching around 1.3 billion people.

As per our analysts at KD Market Insights, the following five players lead the North America Pigmentation disorders treatment market growth :

• AbbVie Inc.
• Bayer AG
• Galderma SA
• L’OREAL SA
• Obagi Cosmeceuticals LLC

Pigmentation Disorders Treatment Market Competitive Landscape

Some of the key players who top the global Pigmentation disorders treatment market share:

• Arcutis Biotherapeutics
• Astellas Pharma Inc.
• Bausch Health Companies Inc
• Dermavant Science Inc.
• Dr Reddy's Laboratories Limited
• Galderma SA
• Glenmark Pharmaceuticals Limited
• Incyte Corporation
• Obagi Cosmeceuticals LLC
• Viatirs Inc.

1. Executive Summary
   1. Market Overview
   2. Key Findings
   3. Market Trends
   4. Market Outlook
2. Introduction
   1. Scope of the Report
   2. Research Methodology
   3. Definitions and Assumptions
   4. Acronyms and Abbreviations
3. Market Dynamics
   1. Drivers
   2. Restraints
   3. Opportunities
   4. Challenges
4. Global Pigmentation Disorders Treatment Market
   1. Market Overview
   2. Market Size and Forecast
   3. Market Segmentation
      1. By Disease type
      2. By Treatment type
      3. By Drugs
      4. By Route of administration
      5. By End-user
      6. By Distribution channel
      7. By Region
5. Market Segmentation by Disease type
   1. 1. Melasma
      2. Vitiligo
      3. Albinism
      4. Post-Inflammatory Hyperpigmentation
      5. Others
6. Market Segmentation by Treatment type
   1. 1. Pharmacological Treatment
      2. Non-invasive Treatment
      3. Surgery
7. Market Segmentation by Drugs
   1. 1.  Calcineurin Inhibitors
      2. Melanocyte-Stimulating Hormone
      3. Others
8. Market Segmentation by Route of administration
   1. 1. Oral
      2. Topical
      3. Others
9. Market Segmentation by End-user
   1. 1. Dermatology Clinics
      2. Aesthetic Clinics
      3. Homecare
      4. Hospitals
      5. Others
10. Market Segmentation by Distribution channel
    1. 1. Hospital Pharmacy
       2. Retail Pharmacy
       3. Online Pharmacy

1. Regional Analysis
   1. North America
      1. United States
         1. Market Size and Forecast
         2. Key Trends and Developments
2. Market Analysis by Disease type, Treatment type, Drugs, Route of administration, End-user, and Distribution channel
3.  
4. 1. 1. 1.  
      2. Canada
         1. Market Size and Forecast
         2. Key Trends and Developments
5. Market Analysis by Disease type, Treatment type, Drugs, Route of administration, End-user, and Distribution channel
   1. 1. Mexico
         1. Market Size and Forecast
         2. Key Trends and Developments
6. Market Analysis by Disease type, Treatment type, Drugs, Route of administration, End-user, and Distribution channel
   1. Europe
      1. United Kingdom
         1. Market Size and Forecast
         2. Key Trends and Developments
7. Market Analysis by Disease type, Treatment type, Drugs, Route of administration, End-user, and Distribution channel
   1. 1. Germany
         1. Market Size and Forecast
         2. Key Trends and Developments
8. Market Analysis by Disease type, Treatment type, Drugs, Route of administration, End-user, and Distribution channel
   1. 1. France
         1. Market Size and Forecast
         2. Key Trends and Developments
9. Market Analysis by Disease type, Treatment type, Drugs, Route of administration, End-user, and Distribution channel
   1. 1. Italy
         1. Market Size and Forecast
         2. Key Trends and Developments
10. Market Analysis by Disease type, Treatment type, Drugs, Route of administration, End-user, and Distribution channel
    1. 1. Spain
          1. Market Size and Forecast
          2. Key Trends and Developments
11. Market Analysis by Disease type, Treatment type, Drugs, Route of administration, End-user, and Distribution channel
    1. 1. Rest of Europe
          1. Market Size and Forecast
          2. Key Trends and Developments
12. Market Analysis by Disease type, Treatment type, Drugs, Route of administration, End-user, and Distribution channel
    1. Asia Pacific
       1. China
          1. Market Size and Forecast
          2. Key Trends and Developments
13. Market Analysis by Disease type, Treatment type, Drugs, Route of administration, End-user, and Distribution channel
    1. 1. Japan
          1. Market Size and Forecast
          2. Key Trends and Developments
14. Market Analysis by Disease type, Treatment type, Drugs, Route of administration, End-user, and Distribution channel
    1. 1. India
          1. Market Size and Forecast
          2. Key Trends and Developments
15. Market Analysis by Disease type, Treatment type, Drugs, Route of administration, End-user, and Distribution channel
    1. 1. Australia
          1. Market Size and Forecast
          2. Key Trends and Developments
16. Market Analysis by Disease type, Treatment type, Drugs, Route of administration, End-user, and Distribution channel
    1. 1. 1. South Korea
          2. Market Size and Forecast
          3. Key Trends and Developments
17. Market Analysis by Disease type, Treatment type, Drugs, Route of administration, End-user, and Distribution channel
    1. 1. Rest of Asia Pacific
          1. Market Size and Forecast
          2. Key Trends and Developments
18. Market Analysis by Disease type, Treatment type, Drugs, Route of administration, End-user, and Distribution channel
    1. Latin America
       1. Brazil
          1. Market Size and Forecast
          2. Key Trends and Developments
19. Market Analysis by Disease type, Treatment type, Drugs, Route of administration, End-user, and Distribution channel
    1. 1. Argentina
          1. Market Size and Forecast
          2. Key Trends and Developments
20. Market Analysis by Disease type, Treatment type, Drugs, Route of administration, End-user, and Distribution channel
    1. 1. Colombia
          1. Market Size and Forecast
          2. Key Trends and Developments
21. Market Analysis by Disease type, Treatment type, Drugs, Route of administration, End-user, and Distribution channel
    1. 1. Rest of Latin America
          1. Market Size and Forecast
          2. Key Trends and Developments
22. Market Analysis by Disease type, Treatment type, Drugs, Route of administration, End-user, and Distribution channel
    1. Middle East & Africa
       1. South Africa
          1. Market Size and Forecast
          2. Key Trends and Developments
23. Market Analysis by Disease type, Treatment type, Drugs, Route of administration, End-user, and Distribution channel
    1. 1. Saudi Arabia
          1. Market Size and Forecast
          2. Key Trends and Developments
24. Market Analysis by Disease type, Treatment type, Drugs, Route of administration, End-user, and Distribution channel
    1. 1. UAE
          1. Market Size and Forecast
          2. Key Trends and Developments
25. Market Analysis by Disease type, Treatment type, Drugs, Route of administration, End-user, and Distribution channel
    1. 1. Rest of Middle East & Africa
          1. Market Size and Forecast
          2. Key Trends and Developments
26. Market Analysis by Disease type, Treatment type, Drugs, Route of administration, End-user, and Distribution channel
27. Competitive Landscape
    1. Market Share Analysis
    2. Company Profiles
    3. Medtronic (Ireland)
    4. IBM
    5. Apple Inc.
    6. Siemens Medical Solutions
    7. Pepperl+Fuchs
    8. Cisco
    9. GE Healthcare
28. Strategic Recommendations
29. Appendix
    1. List of Tables
    2. List of Figures
30. References